Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting
preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in
patients with locally advanced, recurrent, or metastatic cancer associated with one of the
following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.)
sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.)
mismatch repair deficient and/or microsatellite unstable cancers, and 10.) patients who have
exhausted conventional systemic therapy options by using the objective response rate (ORR).